Argenx has a pipeline of in-house and partnered assets that includes antibodies for blood cancers, autoimmune diseases and dyslipidemia. It licensed its tech to AgomAb under a program designed to open up the platform to academic researchers and biotech companies who might exploit it in promising areas.
AgomAb's series A came from investors spanning Belgium, France, Germany and Israel: V-Bio Ventures, Advent France Biotechnology, Boehringer Ingelheim Venture Fund, Omnes and Pontifax. With the cash, AgoMab plans to bring at least one antibody to the IND stage. Along with the Argenx deal and financing, the company also announced its leadership team: Joining Knotnerus are Chief Development Officer Torsten Dreier, Ph.D., who held that role at Argenx, which he also co-founded, and Michieli, the chief scientific officer.
Over time, AgomAbs will add to its clinical and corporate staff, but Knotnerus kept the specifics under wraps.
Een verzelfstandiging uit de Argen-x stal in zekere zin, AgomAb kan heel goed een succes worden en dan wordt Argen-X daar ook beter van. Gezien de kwaliteit van de investeerders zit er muziek in.